Gene · 3909
Papers1,589
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,589
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Measurement properties of instruments used to measure health-related quality of life in pediatric and adults patients with inherited epidermolysis bullosa: A systematic review and meta-analysis protocol. | PLoS One | 2025 | 40971360 | PubTator, text mining | PubMed |
| Identifying novel genetic variants in epidermolysis Bullosa among Middle Eastern Arab Families: Insights from whole exome sequencing and computational analysis. | PLoS One | 2025 | 40956805 | PubTator, text mining | PubMed |
| Bladder Cancer: Role of Circular RNAs in Oncogenesis, Tumor Suppression, and Therapeutic Target Identification. | Cancer Genomics Proteomics | 2025 | 40883021 | PubTator, text mining | PubMed |
| HEYL-mediated activation of LAMA3 influences radiotherapy response in esophageal cancer. | Esophagus | 2025 | 40833662 | PubTator, text mining | PubMed |
| Junctional Epidermolysis Bullosa Caused by a Hemiallelic Nonsense Mutation in LAMA3 Revealed by 18q11.2 Microdeletion. | Int J Mol Sci | 2025 | 40806473 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
| SPP1 + macrophages facilitate pancreatic cancer progression via ITGB6-mediated interactions: evidence from integrated multi-omics analysis and experimental validation. | Immunol Res | 2025 | 40719841 | PubTator, text mining | PubMed |
| An extracellular matrix niche secreted by epithelial cells drives intestinal organoid formation. | Dev Cell | 2025 | 40680738 | PubTator, text mining | PubMed |
| LAMA3 overexpression enhances proliferation, migration and invasion in esophageal squamous cell carcinoma based on bioinformatics and experimental validation. | Sci Rep | 2025 | 40628792 | PubTator, text mining | PubMed |
| Induced Pluripotent (iPSC) and Mesenchymal (MSC) Stem Cells for In Vitro Disease Modeling and Regenerative Medicine. | Int J Mol Sci | 2025 | 40565081 | PubTator, text mining | PubMed |
| A model of basement membrane-related regulators for prediction of prognoses in esophageal cancer and verification in vitro. | BMC Cancer | 2025 | 40234833 | PubTator, text mining | PubMed |
| Comprehensive pan-cancer analysis of LAMA3: implications for prognosis and immunotherapy. | Am J Transl Res | 2025 | 40092111 | PubTator, text mining | PubMed |
| miR-212-5p Regulates PM2.5-Induced Apoptosis by Targeting LAMC2 and LAMA3. | Int J Mol Sci | 2025 | 40004224 | PubTator, text mining | PubMed |
| Caveolin 1 and 2 enhance the proliferative capacity of BCAM-positive corneal progenitors. | Sci Rep | 2025 | 39994275 | PubTator, text mining | PubMed |
| SRSF12 deficiency enhances tumor innervation and accelerates pancreatic tumorigenesis. | Cancer Lett | 2025 | 39986371 | PubTator, text mining | PubMed |
| Therapeutic potential of recombinant human type XVII collagen in wound healing and bullous pemphigoid: From bench to bedside. | Eur J Pharm Sci | 2025 | 39914723 | PubTator, text mining | PubMed |
| Knockdown of LAMA3 enhances the sensitivity of colon cancer to oxaliplatin by regulating the Hippo-YAP pathway. | Biochim Biophys Acta Mol Basis Dis | 2025 | 39798821 | PubTator, text mining | PubMed |
| Identification of a novel variant of LAMB3 in a patient with a distinct junctional epidermolysis bullosa laryngo-onycho-cutaneous syndrome phenotype. | Clin Exp Dermatol | 2025 | 39420565 | PubTator, text mining | PubMed |
| Anti-Laminin β4 IgG Drives Tissue Damage in Anti-p200 Pemphigoid and Shows Interactions with Laminin α3 and γ1/2 Chains. | J Invest Dermatol | 2025 | 39320300 | PubTator, text mining | PubMed |
| Unlocking Clinical Insights: Lymphocyte-Specific Protein Tyrosine Kinase Candidates as Promising Therapeutic Targets for Pancreatic Cancer Risk Stratification. | Cancer Biother Radiopharm | 2025 | 38837745 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3909/papers?page=3